GH Research is a Dublin-based biotech, focused on developing a novel and proprietary inhalable 5- Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapy for the treatment of patients with Treatment Resistant Depression (TRD). The company is also researching an injectable formulation of the drug.
The company currently has filed four patents patents for its drug candidates, GH001 and GH002. You can learn more about it’s pipeline here.